<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40511773</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism Prophylaxis Practice Patterns, Outcomes, and Risk Stratification After Surgery for IBD: A National Surgical Quality Improvement Program IBD Collaborative Study.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1073</EndPage><MedlinePgn>1062-1073</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003833</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal venous thromboembolism chemoprophylaxis strategy after surgery for IBD is not defined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the real-world efficacy of chemoprophylaxis strategies after surgery for IBD in a retrospective cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of medical records from the National Surgical Quality Improvement Program IBD Collaborative of patients treated between July 2020 to October 2023.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Seventeen medical centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with IBD undergoing colectomy and/or proctectomy were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Chemoprophylaxis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Thirty-day venous thromboembolism (clot) rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During 3 years, 1797 patients were eligible for chemoprophylaxis and included in the analysis, of whom 44 (2.4%) developed a clot within 30 days: 50% before and after discharge, respectively. Clots were diagnosed a median of 9 days postoperatively. The most common clots were portomesenteric (39%), pulmonary embolism (27%), and upper extremity (18%). Before discharge, clot rates differed by chemoprophylaxis strategy: enoxaparin (0.57%) versus unfractionated heparin (2.1%, p = 0.006). Any extended chemoprophylaxis was used in 50.5%, and clot rates differed by strategy: no extended chemoprophylaxis (1.4%), enoxaparin (0.63%), and others (3.5%, p = 0.01). Chemoprophylaxis strategies were not associated with bleeding complications. Multivariable analysis revealed that preoperative systemic inflammatory response syndrome ( p = 0.0005) and extended resections ( p &lt; 0.0001) were independent risk factors for postoperative clots. Patients with 0, 1, or 2 risk factors had clot rates of 1.2%, 4.0%, and 13.5%, respectively ( p &lt; 0.0001). Inpatient and extended prophylaxis with enoxaparin were independently associated with a lower risk of clots both before and after discharge ( p = 0.002 and p = 0.02, respectively), with relative risk reductions of 74.8% and 72.6%. For a clot rate of 2.5%, the estimated number needed to treat with enoxaparin in-hospital and postdischarge was 54 and 55 patients, respectively.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The limitations to this study were generalizability and selection bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After IBD surgery, venous thromboembolism chemoprophylaxis with enoxaparin was associated with a decreased risk of clot formation before and after discharge. Patients at highest risk may benefit the most from extended chemoprophylaxis. See Video Abstract .</AbstractText><AbstractText Label="PATRONES DE PRCTICA, RESULTADOS Y ESTRATIFICACIN DEL RIESGO EN LA PROFILAXIS DE LA TROMBOEMBOLIA VENOSA TRAS CIRUGA POR ENFERMEDAD INFLAMATORIA INTESTINAL ESTUDIO COLABORATIVO DEL PROGRAMA NACIONAL DE MEJORA DE LA CALIDAD QUIRRGICA SOBRE EII" NlmCategory="UNASSIGNED">ANTECEDENTES:No se ha definido la estrategia &#xf3;ptima de quimioprofilaxis de la tromboembolia venosa tras la cirug&#xed;a por enfermedad inflamatoria intestinal.OBJETIVO:Investigar la eficacia real de las estrategias de quimioprofilaxis tras la cirug&#xed;a por enfermedad inflamatoria intestinal en una cohorte retrospectiva.DISE&#xd1;O:Entre julio de 2020 y octubre de 2023, la Colaboraci&#xf3;n sobre Enfermedad Inflamatoria Intestina deel Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica.ENTORNO:Diecisiete centros m&#xe9;dicos.PACIENTES:Pacientes con enfermedad inflamatoria intestinal sometidos a colectom&#xed;a y/o proctectom&#xed;a.INTERVENCIONES:Quimioprofilaxis.PRINCIPALES MEDIDAS DE RESULTADO:Tasas de tromboembolia venosa (co&#xe1;gulos) a 30 d&#xed;as.RESULTADOS:Durante tres a&#xf1;os, 1797 pacientes fueron elegibles para quimioprofilaxis y fueron analizados, de los cuales 44 (2.4 %) desarrollaron un co&#xe1;gulo en un plazo de 30 d&#xed;as: el 50 % antes y despu&#xe9;s del alta, respectivamente. Los co&#xe1;gulos se diagnosticaron una mediana de 9 d&#xed;as despu&#xe9;s de la operaci&#xf3;n. Los co&#xe1;gulos m&#xe1;s frecuentes fueron portomesent&#xe9;ricos (39 %), embolia pulmonar (27 %) y extremidades superiores (18 %). Antes del alta, las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia de quimioprofilaxis: enoxaparina (0.57 %) frente a heparina no fraccionada (2.1 %), p = 0.006. Se utiliz&#xf3; una quimioprofilaxis prolongada en el 50.5 % de los casos y las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia: sin quimioprofilaxis prolongada (1.4 %), enoxaparina (0.63 %) y otras (3.5 %) p = 0.01. Las estrategias de quimioprofilaxis no se asociaron con complicaciones hemorr&#xe1;gicas. El an&#xe1;lisis multivariable revel&#xf3; que el s&#xed;ndrome de respuesta inflamatoria sist&#xe9;mica preoperatoria ( p = 0.0005) y las resecciones extendidas ( p &lt; 0.0001) eran factores de riesgo independientes para los co&#xe1;gulos postoperatorios. Los pacientes con 0, 1 o 2 factores de riesgo tuvieron tasas de co&#xe1;gulos del 1.2 %, 4.0 % y 13.5 %, respectivamente ( p &lt; 0.0001). La profilaxis hospitalaria y prolongada con enoxaparina se asoci&#xf3; de forma independiente con un menor riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta ( p = 0.002 y p = 0.02, respectivamente), con reducciones del riesgo relativo del 74.8 % y el 72.6 %. Para una tasa de co&#xe1;gulos del 2.5 %, el n&#xfa;mero estimado de pacientes que deb&#xed;an recibir tratamiento con enoxaparina durante la hospitalizaci&#xf3;n y despu&#xe9;s del alta fue de 54 y 55, respectivamente.LIMITACIONES:Generalizaci&#xf3;n; sesgo de selecci&#xf3;n.CONCLUSIONES:Tras la cirug&#xed;a por enfermedad inflamatoria intestinal, la quimioprofilaxis de la tromboembolia venosa con enoxaparina se asoci&#xf3; con una disminuci&#xf3;n del riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta. Los pacientes con mayor riesgo pueden beneficiarse m&#xe1;s de una quimioprofilaxis prolongada. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-2549-9042</Identifier><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2646-0625</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of California, San Diego School of Medicine, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana G</ForeName><Initials>LG</Initials><Identifier Source="ORCID">0000-0003-3418-6774</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Colorectal Surgery Program, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-9138-186</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla F</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0002-9526-0643</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Cincinnati, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0382-880</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-8273-9471</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Stanford Health Care, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krane</LastName><ForeName>Mukta K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-4872-1061</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Washington Medical Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5814-3915</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-2014-0302</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-4010-5275</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Penn State Health, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mount Sinai Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NSQIP IBD Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemoprophylaxis</Keyword><Keyword MajorTopicYN="N">Colectomy</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Direct oral anticoagulants</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Ileoanal pouch</Keyword><Keyword MajorTopicYN="N">Low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">Proctectomy</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Anzlovar</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batten</LastName><ForeName>JoAnn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belding-Schmitt</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohne</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Leon</LastName><ForeName>Elmer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devaney</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Divino</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germaine</LastName><ForeName>Odile</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyette</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilbert</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirbe</LastName><ForeName>Mitzi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huggins</LastName><ForeName>Pam</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyke</LastName><ForeName>Roxanne</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keenan</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khaitov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunitake</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lavryk</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liska</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messaris</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Reba</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mutch</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narsule</LastName><ForeName>Chaitan</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paquette</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paredes</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prachand</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramamoorthy</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricciardi</LastName><ForeName>Rocco</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenkranz</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sansone</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Radhika</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spain</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinhagen</LastName><ForeName>Randolph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strong</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylla</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Anila</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Valora</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomaska</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torbela</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valerian</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whyte</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>8</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40511773</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003833</ArticleId><ArticleId IdType="pii">00003453-990000000-00977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brady MT, Patts GJ, Rosen A, et al. Postoperative venous thromboembolism in patients undergoing abdominal surgery for IBD: a common but rarely addressed problem. Dis Colon Rectum. 2017;60:61&#x2013;67.</Citation></Reference><Reference><Citation>GamalEldin M, DeHaan RK, Sklow B, et al. Portomesenteric venous thrombosis after colorectal surgery for inflammatory bowel disease: a call to action? [ASCRS abstract POD232]. Dis Colon Rectum. 2021;64:e109&#x2013;e364.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Cima RR, Habermann EB. Timing and location of venous thromboembolisms after surgery for inflammatory bowel disease. J Surg Res. 2024;296:563&#x2013;570.</Citation></Reference><Reference><Citation>Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum. 2012;55:1138&#x2013;1144.</Citation></Reference><Reference><Citation>Bergqvist D, Agnelli G, Cohen AT, et al.; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975&#x2013;980.</Citation></Reference><Reference><Citation>Fleming F, Gaertner W, Ternent CA, et al. The American Society of Colon and Rectal Surgeons clinical practice guideline for the prevention of venous thromboembolic disease in colorectal surgery. Dis Colon Rectum. 2018;61:14&#x2013;20.</Citation></Reference><Reference><Citation>Eisenstein S, Holubar SD, Hilbert N, et al. The ACS National Surgical Quality Improvement Program-Inflammatory Bowel Disease Collaborative: design, implementation, and validation of a disease-specific module. Inflamm Bowel Dis. 2019;25:1731&#x2013;1739.</Citation></Reference><Reference><Citation>Greaves SW, Holubar SD. Preoperative hospitalization is independently associated with increased risk for venous thromboembolism in patients undergoing colorectal surgery: a national surgical quality improvement program database study. Dis Colon Rectum. 2015;58:782&#x2013;791.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Lightner AL, Habermann EB. Do patients with inflammatory bowel disease have a higher postoperative risk of venous thromboembolism or do they undergo more high-risk operations? Ann Surg. 2020;271:325&#x2013;331.</Citation></Reference><Reference><Citation>Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17(suppl 3):304&#x2013;312.</Citation></Reference><Reference><Citation>Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632&#x2013;634.</Citation></Reference><Reference><Citation>Benlice C, Holubar SD, Gorgun E, et al. Extended venous thromboembolism prophylaxis after elective surgery for IBD patients: nomogram-based risk assessment and prediction from nationwide cohort. Dis Colon Rectum. 2018;61:1170&#x2013;1179.</Citation></Reference><Reference><Citation>Cheong JY, Connelly TM, Russell T, et al. Venous thromboembolism risk stratification for patients undergoing surgery for IBD using a novel six factor scoring system using NSQIP-IBD registry. ANZ J Surg. 2023;93:1620&#x2013;1625.</Citation></Reference><Reference><Citation>Cordell WH. Number needed to treat (NNT). Ann Emerg Med. 1999;33:433&#x2013;436.</Citation></Reference><Reference><Citation>Montero Ruiz E, Baldominos Utrilla G, L&#xf3;pez &#xc1;lvarez J, Santolaya Perrin R. Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients. Thromb Res. 2011;128:440&#x2013;445.</Citation></Reference><Reference><Citation>Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422&#x2013;1430.</Citation></Reference><Reference><Citation>Lee CHA, Jia X, Lipman JM, et al. Defining the economic burden of perioperative venous thromboembolism in inflammatory bowel disease in the United States. Dis Colon Rectum. 2021;64:871&#x2013;880.</Citation></Reference><Reference><Citation>Leeds IL, DiBrito SR, Canner JK, Haut ER, Safar B. Cost-benefit limitations of extended, outpatient venous thromboembolism prophylaxis following surgery for Crohn&#x2019;s disease. Dis Colon Rectum. 2019;62:1371&#x2013;1380.</Citation></Reference><Reference><Citation>Leeds IL, Haut ER. Are we really supposed to start giving venous thromboembolism prophylaxis for a month after outpatient surgery? JAMA Surg. 2019;154:1133.</Citation></Reference><Reference><Citation>Prien C, Ribakow D, Steele SR, et al. What about patient cost? Defining copay and out-of-pocket costs of extended venous thromboembolism chemoprophylaxis after colorectal surgery. J Gastrointest Surg. 2023;27:152&#x2013;154.</Citation></Reference><Reference><Citation>Stewart KT, Jafari H, Pattillo J, et al. Avoiding the needle: a quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery. Gynecol Oncol. 2024;188:131&#x2013;139.</Citation></Reference><Reference><Citation>Ogilvie JW Jr, Khan MT, Hayakawa E, Parker J, Luchtefeld MA. Low-dose rivaroxaban as extended prophylaxis reduces postdischarge venous thromboembolism in patients with malignancy and IBD. Dis Colon Rectum. 2024;67:457&#x2013;465.</Citation></Reference><Reference><Citation>Holubar SD, Eisenstein S, Bordeianou L, et al. Venous thromboembolism prophylaxis practice patterns, outcomes, and risk stratification after surgery for inflammatory bowel disease: a NSQIP IBD Collaborative study. Dis Colon Rectum. 2025;68:e228&#x2013;e229.</Citation></Reference><Reference><Citation>Cordova-Cassia C, Wong D, Cotter MB, Cataldo TE, Poylin VY. Patient&#x2019;s compliance is a contributor to failure of extended antithrombotic prophylaxis in colorectal surgery: prospective cohort study. Surg Endosc. 2022;36:267&#x2013;273.</Citation></Reference><Reference><Citation>Elzaafarany A, Tawfik A, Igbekele T, Day A. EP-351 Extended VTE prophylaxis in patients undergoing elective surgery for colorectal cancer in a district general hospital and its compliance with NICE guidelines. Br J Surg. 2022;109(Suppl 5):znac245.091.</Citation></Reference><Reference><Citation>Yeung T, Ng S, Sidhu R, Ali M. 463 Adherence to extended venous thromboembolism prophylaxis for post operative resection of colorectal malignancies. Br J Surg. 2023;110(Suppl 7):znad258.105.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>